What is a normal result for the BCR-ABL1 (Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Normal BCR-ABL1 Test Result

A normal BCR-ABL1 test result is undetectable BCR-ABL1 transcripts, reported as "BCR-ABL1 not detected" or "negative." This indicates the absence of the Philadelphia chromosome-associated fusion gene that characterizes chronic myeloid leukemia (CML).

Understanding BCR-ABL1 Testing Context

The BCR-ABL1 test detects the fusion gene resulting from the reciprocal translocation t(9;22)(q34;q11.2), which is the hallmark of CML 1. In healthy individuals without CML or Philadelphia chromosome-positive acute lymphoblastic leukemia, this fusion gene should be completely absent 1.

Reporting Standards for Normal Results

  • In individuals without CML: The result should simply state "BCR-ABL1 not detected" or "negative" 1
  • No quantitative value is assigned when the fusion transcript is absent in screening scenarios 1

Important Distinction: Monitoring vs. Screening

The detailed molecular response (MR) classifications you may encounter—such as MR4, MR4.5, or MR5—apply only to CML patients undergoing treatment monitoring, not to normal screening results 2:

  • MR4: ≤0.01% BCR-ABL1 on International Scale (IS) with adequate reference gene transcripts 2
  • MR4.5: ≤0.0032% BCR-ABL1 IS or undetectable disease with ≥32,000 ABL1 transcripts 2
  • MR5: ≤0.001% BCR-ABL1 IS or undetectable disease with ≥100,000 ABL1 transcripts 2

These classifications represent deep molecular responses in treated CML patients, not normal baseline values 2.

Technical Considerations

  • Reference gene requirements (minimum 10,000 ABL1 or 24,000 GUSB transcripts per replicate) apply only when assessing molecular response depth in CML patients 2
  • Limit of detection: Modern qRT-PCR assays can detect as few as 3 BCR-ABL1 copies with 95% confidence, but this sensitivity is relevant only for monitoring residual disease 2

Clinical Pitfall

Do not confuse "undetectable BCR-ABL1" in a treated CML patient (indicating deep molecular response) with a normal screening result in someone without CML. The former requires specific reference gene thresholds and International Scale standardization 2, while the latter is simply a negative test 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.